Literature DB >> 6287039

Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo.

D A Thorley-Lawson, C A Poodry.   

Abstract

The majority of hybridomas we have characterized against Epstein-Barr virions react with the major glycoproteins gp350 and gp220 (gp350/220). One of these antibodies, ID4C-1, neutralizes virus infection in vitro. The presence of gp350/220 on the viral envelope could be confirmed directly by immunoelectron microscopy. We used lectin affinity (ricin) and immunoaffinity (ID4C-1) to purify gp350/220 and show that this material is able to induce potent virus-neutralizing antibodies. Absorption of four human and one rabbit anti-Epstein-Barr virus sera with purified gp350/220 suggests that this is the primary component responsible for generating neutralizing antibodies in vivo.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6287039      PMCID: PMC256176     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

1.  Rapid isolation of antigens from cells with a staphylococcal protein A-antibody adsorbent: parameters of the interaction of antibody-antigen complexes with protein A.

Authors:  S W Kessler
Journal:  J Immunol       Date:  1975-12       Impact factor: 5.422

2.  Proteins of Epstein-Barr virus. I. Analysis of the polypeptides of purified enveloped Epstein-Barr virus.

Authors:  M Dolyniuk; R Pritchett; E Kieff
Journal:  J Virol       Date:  1976-03       Impact factor: 5.103

3.  Cytotoxic effector cells specific for B Cell lines transformed by Epstein-Barr virus are present in patients with infectious mononucleosis.

Authors:  E Svedmyr; M Jondal
Journal:  Proc Natl Acad Sci U S A       Date:  1975-04       Impact factor: 11.205

4.  Assay for Epstein-Barr virus based on stimulation of DNA synthesis in mixed leukocytes from human umbilical cord blood.

Authors:  J Robinson
Journal:  J Virol       Date:  1975-05       Impact factor: 5.103

5.  Characterization of cross-reacting antigens on the Epstein-Barr virus envelope and plasma membranes of producer cells.

Authors:  D A Thorley-Lawson
Journal:  Cell       Date:  1979-01       Impact factor: 41.582

6.  Relationship between the EBV-associated membrane antigen on Burkitt lymphoma cells and the viral envelope, demonstrated by immunoferritin labelling.

Authors:  D Silvestre; F M Kourilsky; G Klein; Y Yata; C Neauport-Sautes; J P Levy
Journal:  Int J Cancer       Date:  1971-09-15       Impact factor: 7.396

7.  An immunoferritin study of a Burkitt lymphoma cell line harboring EB virus particles.

Authors:  K Sugawara; T Osato
Journal:  Gan       Date:  1970-06

8.  Chemical coupling of proteins to agarose.

Authors:  J Porath; R Axen; S Ernback
Journal:  Nature       Date:  1967-09-30       Impact factor: 49.962

9.  The ultrastructural basis of alveolar-capillary membrane permeability to peroxidase used as a tracer.

Authors:  E E Schneeberger-Keeley; M J Karnovsky
Journal:  J Cell Biol       Date:  1968-06       Impact factor: 10.539

10.  Suppression of in vitro Epstein-Barr virus infection. A new role for adult human T lymphocytes.

Authors:  D A Thorley-Lawson; L Chess; J L Strominger
Journal:  J Exp Med       Date:  1977-08-01       Impact factor: 14.307

View more
  56 in total

1.  Infectious Epstein-Barr virus lacking major glycoprotein BLLF1 (gp350/220) demonstrates the existence of additional viral ligands.

Authors:  A Janz; M Oezel; C Kurzeder; J Mautner; D Pich; M Kost; W Hammerschmidt; H J Delecluse
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Mapping of B-cell epitopes on the polypeptide chain of the Epstein-Barr virus major envelope glycoprotein and candidate vaccine molecule gp340.

Authors:  R J Pither; C X Zhang; C Shiels; J Tarlton; S Finerty; A J Morgan
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

Review 3.  EBV Persistence--Introducing the Virus.

Authors:  David A Thorley-Lawson
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

4.  Kinetics of Epstein-Barr Virus (EBV) Neutralizing and Virus-Specific Antibodies after Primary Infection with EBV.

Authors:  Wei Bu; Gregory M Hayes; Hui Liu; Lorraine Gemmell; David O Schmeling; Pierce Radecki; Fiona Aguilar; Peter D Burbelo; Jennifer Woo; Henry H Balfour; Jeffrey I Cohen
Journal:  Clin Vaccine Immunol       Date:  2016-04-04

Review 5.  Epstein-barr virus: environmental trigger of multiple sclerosis?

Authors:  Jan D Lünemann; Thomas Kamradt; Roland Martin; Christian Münz
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

6.  Characterization and expression of a glycoprotein encoded by the Epstein-Barr virus BamHI I fragment.

Authors:  M Mackett; M J Conway; J R Arrand; R S Haddad; L M Hutt-Fletcher
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

7.  Expression of the Epstein-Barr virus gp350/220 gene in rodent and primate cells.

Authors:  Y Whang; M Silberklang; A Morgan; S Munshi; A B Lenny; R W Ellis; E Kieff
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

8.  High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis.

Authors:  Eric R Weiss; Galit Alter; Javier Gordon Ogembo; Jennifer L Henderson; Barbara Tabak; Yasin Bakiş; Mohan Somasundaran; Manuel Garber; Liisa Selin; Katherine Luzuriaga
Journal:  J Virol       Date:  2016-12-16       Impact factor: 5.103

9.  Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells.

Authors:  Wei Bu; M Gordon Joyce; Hanh Nguyen; Dalton V Banh; Fiona Aguilar; Zeshan Tariq; Moh Lan Yap; Yusuke Tsujimura; Rebecca A Gillespie; Yaroslav Tsybovsky; Sarah F Andrews; Sandeep R Narpala; Adrian B McDermott; Michael G Rossmann; Yasuhiro Yasutomi; Gary J Nabel; Masaru Kanekiyo; Jeffrey I Cohen
Journal:  Immunity       Date:  2019-04-09       Impact factor: 31.745

10.  Murine gammaherpesvirus-68 glycoprotein B presents a difficult neutralization target to monoclonal antibodies derived from infected mice.

Authors:  Laurent Gillet; Michael B Gill; Susanna Colaco; Christopher M Smith; Philip G Stevenson
Journal:  J Gen Virol       Date:  2006-12       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.